The role of translationally controlled tumor protein in tumor growth and metastasis of colon adenocarcinoma cells

Journal of Proteome Research

Volumn 9, Issue 1, 2010, Pages 40-49

  Qiang, Ma ^a   Yan, Geng ^b   Weiwen, Xu ^a   Yingsong, Wu ^a   Fuli, He ^c   Wen, Shu ^a   Maoliang, Huang ^a   Hongyan, Du ^a   Ming, Li ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b The 303rd Hospital of PLA   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

2D gel electrophoresis; MALDI TOF TOF MS; Mass spectrometry; Metastasis; Proteomics; Translationally controlled tumor protein (TCTP)

Indexed keywords

PROTEASOME; PROTEOME; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLON ADENOCARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENOCARCINOMA; ANIMALS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; PROTEIN BIOSYNTHESIS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73649099883     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr9001367     Document Type: Article

References (38)

1. Gachet, Y.; Tournier, S.; Lee, M.; Lazaris-Karatzas, A.; Poulton, T.; Bommer, U. A. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J. Cell Sci. 1999, 112 (Pt. 8), 1257-1271.
2. Bommer, U. A.; Thiele, B. J. The translationally controlled tumour protein (TCTP). Int. J. Biol. Chem. Cell Biol. 2004, 36 (3), 379-385.
3. Chung, S.; Kim, M.; Choi, W.-J.; Chung, J.-K.; Lee, K. Expression of translationally controlled tumor protein mRNA in human colon cancer. Cancer Lett. 2000, 156 (2), 185-190.
4. Tuynder, M.; Susini, L.; Prieur, S.; Besse, S.; Fiucci, G.; Amson, R.; Telerman, A. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (23), 14976-14981.
5. Tuynder, M.; Fiucci, G.; Prieur, S.; Lespagnol, A.; Geant, A.; Beaucourt, S.; Duflaut, D.; Besse, S.; Susini, L.; Cavarelli, J.; Moras, D.; Amson, R.; Telerman, A. Translationally controlled tumor protein is a target of tumor reversion. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (43), 15364-15369.
6. Stierum, R.; Gaspari, M.; Dommels, Y.; Ouatas, T.; Pluk, H.; Jespersen, S.; Vogels, J.; Verhoeckx, K.; Groten, J.; van Ommen, B. Proteome analysis reveals novel proteins associated with proliferation and differentiation of the colorectal cancer cell line Caco-2. Biochim. Biophys. Acta 2003, 1650 (1-2), 73-91.
7. Slaby, O.; Sobkova, K.; Svoboda, M.; Garajova, I.; Fabian, P.; Sachlova, M.; Smerdova, T.; Knoflickova, D.; Vyzula, R. Altered expression of heat shock protein 110 (HSP110), hypoxia upregulated 1 (HYOU1) and translationally controlled tumor protein (TCTP) during colorectal cancer progression. Eur. J. Cancer Suppl. 2008, 6 (9), 129-129.
8. Brummelkamp, T. R.; Bernards, R.; Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296 (5567), 550-553.
9. Sui, G.; Soohoo, C.; Affar el, B.; Gay, F.; Shi, Y.; Forrester, W. C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (8), 5515-5520.
10. Abu-Hamad, S.; Sivan, S.; Shoshan-Barmatz, V. The expression level of the voltage-dependent anion channel controls life and death of the cell. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (15), 5787-5792.
11. Drewinko, B.; Romsdahl, M. M.; Yang, L. Y.; Ahearn, M. J.; Trujillo, J. M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976, 36 (2 Pt 1), 467-475.
12. Fish, R. J.; Kruithof, E. K. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol. Biol. 2004, 5, 9.
13. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25 (4), 402-408.
14. Kaneda, T.; Sonoda, Y.; Ando, K.; Suzuki, T.; Sasaki, Y.; Oshio, T.; Tago, M.; Kasahara, T. Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett. 2008, 270 (2), 354-361.
15. Yan, C.; Han, R. Genistein suppresses adhesion-induced protein tyrosine phosphorylation and invasion of B16-BL6 melanoma cells. Cancer Lett. 1998, 129 (1), 117-124.
16. Murao, L. E.; Shisler, J. L. The MCV MC159 protein inhibits late, but not early, events of TNF-alpha-induced NF-kappaB activation. Virology 2005, 340 (2), 255-264.
17. Bartholin, L.; Guindon, S.; Martel, S.; Corbo, L.; Rimokh, R. Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter. Gene 2007, 393 (1-2), 153-162.
18. Ji, L. L.; Gomez-Cabrera, M. C.; Steinhafel, N.; Vina, J. Acute exercise activates nuclear factor (NF)-kappaB signaling pathway in rat skeletal muscle. FASEB J. 2004, 18 (13), 1499-1506.
19. Rychahou, P. G.; Jackson, L. N.; Silva, S. R.; Rajaraman, S.; Evers, B. M. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann. Surg. 2006, 243 (6), 833-142, discussion 843-844.
20. Palumbo, R.; Galvez, B. G.; Pusterla, T.; De Marchis, F.; Cossu, G.; Marcu, K. B.; Bianchi, M. E. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J. Cell Biol. 2007, 179 (1), 33-40.
21. Mercurio, F.; Murray, B. W.; Shevchenko, A.; Bennett, B. L.; Young, D. B.; Li, J. W.; Pascual, G.; Motiwala, A.; Zhu, H.; Mann, M.; Manning, A. M. IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol. Cell. Biol. 1999, 19 (2), 1526-1538.
22. Van't Veer, L. J.; Weigelt, B. Road map to metastasis. Nat. Med. 2003, 9 (8), 999-1000.
23. Hiraoka, K.; Kimura, T.; Logg, C. R.; Tai, C. K.; Haga, K.; Lawson, G. W.; Kasahara, N. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res. 2007, 67 (11), 5345-5353.
24. Bommer, U. A.; Thiele, B. J. The translationally controlled tumour protein (TCTP). Int. J. Biochem. Cell Biol. 2004, 36 (3), 379-385.
25. Lafreniere, R.; Rosenberg, S. A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J. Natl. Cancer Inst. 1986, 76 (2), 309-322.
26. Giavazzi, R.; Jessup, J. M.; Campbell, D. E.; Walker, S. M.; Fidler, I. J. Experimental nude mouse model of human colorectal cancer liver metastases. J. Natl. Cancer Inst. 1986, 77 (6), 1303-1308.
27. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3 (6), 453-458.
28. D'Alessandro, A.; Pieroni, L.; Ronci, M.; D'Aguanno, S.; Federici, G.; Urbani, A. Proteasome inhibitors therapeutic strategies for cancer. Recent Pat. Anti-Cancer Drug Discovery 2009, 4 (1), 73-82.
29. Uddin, S.; Ahmed, M.; Bavi, P.; El-Sayed, R.; Al-Sanea, N.; Abdul-Jabbar, A.; Ashari, L. H.; Alhomoud, S.; Al-Dayel, F.; Hussain, A. R.; Al-Kuraya, K. S. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008, 68 (9), 3379-3388.
30. Smith, L.; Lind, M. J.; Drew, P. J.; Cawkwell, L. The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy. Eur. J. Cancer 2007, 43 (16), 2330-2338.
31. Iancu-Rubin, C.; Atweh, G. F. p27(Kip1) and stathmin share the stage for the first time. Trends Cell Biol. 2005, 15 (7), 346-348.
32. Evans, A.; Lennard, T. W.; Davies, B. R. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing. J. Surg. Oncol. 2004, 88 (2), 86-99.
33. Lotze, M. T.; Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5 (4), 331-342.
34. Kuniyasu, H.; Chihara, Y.; Takahashi, T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 2003, 10 (2), 445-448.
35. Kuniyasu, H.; Sasaki, T.; Sasahira, T.; Ohmori, H.; Takahashi, T. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 2004, 71 (3), 129-136.
36. Sasahira, T.; Akama, Y.; Fujii, K.; Kuniyasu, H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch. 2005, 446 (4), 411-415.
37. Bassi, R.; Giussani, P.; Anelli, V.; Colleoni, T.; Pedrazzi, M.; Patrone, M.; Viani, P.; Sparatore, B.; Melloni, E.; Riboni, L. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J. Neurooncol. 2008, 87 (1), 23-33.
38. Lin, Y. H.; Park, Z. Y.; Lin, D.; Brahmbhatt, A. A.; Rio, M. C.; Yates, J. R.; Klemke, R. L. Regulation of cell migration and survival by focal adhesion targeting of Lasp-1. J. Cell Biol. 2004, 165 (3), 421-432.